FDA campaign H-1178-2026
Class IHazard
FDA analysis revealed the presence of unapproved ingredients including tianeptine, 1,4 DMAA, and aniracetam.
Distribution
The recalled product was distributed to customers nationwide from April 2022 until December 8, 2025
REKALLD area-alert coverage: nationwide (our reading of the distribution above)
The text above is quoted verbatim from the FDA record. Confirm the affected units and the remedy with the manufacturer or FDA. Recall data may be incomplete, delayed, or superseded.